MedTrace Logo

Clinical Efficacy and Safety of Perampanel Monotherapy in the Treatment of Children With Focal Epilepsy

NCT05497193 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 280

Last updated 2022-08-11

No results posted yet for this study

Summary

This project is a multicenter prospective study. By retrieving outpatient medical records and collecting clinical data of epilepsy patients, the efficacy and safety of single-drug perampanel in patients with focal epilepsy were analyzed.

Conditions

  • Focal Epilepsy

Interventions

DRUG

perampanel

China's state food and drug administration approved indications for adults and children aged 4 or more focal epileptic hair company or not with secondary comprehensive seizures of epilepsy, adding treatment, in July 2020 to monotherapy without clinical approval, the current domestic perampanel monotherapy clinical effectiveness and safety of focal epilepsy in children have not been reported.

Sponsors & Collaborators

  • Yang Xinwei

    lead OTHER

Principal Investigators

  • xinwei yang, doctor · hospital doctor

Eligibility

Min Age
4 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-07-01
Primary Completion
2023-03-20
Completion
2023-10-20

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05497193 on ClinicalTrials.gov